ARCA biopharma Inc (ABIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ARCA biopharma Inc (ABIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7974
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment and prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. It provides medical treatment to the individual genetic characteristics of each patient and personalized medicine approach to drug development. ARCA also develops AB171, a thiol-substituted isosorbide mononitrate for genetically targeted treatment of peripheral arterial disease and heart failure. The company works in partnership with universities to improve the health of cardiovascular patients. ARCA is headquartered in Westminster, Colorado, the US.

ARCA biopharma Inc (ABIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12
Equity Offering 13
ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13
Arca Biopharma Raises USD37 Million in Private Placement of Units 14
ARCA biopharma Files Registration Statement For Public Offering Of Securities For US$75 Million 16
Arca Biopharma Completes Public Offering Of Shares For US$8.7 Million 17
Arca Biopharma Completes Public Offering Of Preferred Shares For US$20 Million 18
Arca Biopharma Completes Private Placement Of Securities For US$1.25 Million 19
ARCA biopharma Completes Public Offering Of Shares For US$0.7 Million 20
Arca Biopharma Completes Private Placement Of Units For US$0.25 Million 21
ARCA biopharma Completes Private Placement Of Units For US$0.325 Million 22
ARCA biopharma Completes Public Offering Of Units For US$1 Million 23
ARCA biopharma Inc – Key Competitors 25
ARCA biopharma Inc – Key Employees 26
ARCA biopharma Inc – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
May 08, 2018: ARCA Biopharma announces first quarter 2018 financial results and provides corporate update 28
Mar 22, 2018: ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update 29
Nov 09, 2017: ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update 30
Aug 03, 2017: ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update 31
May 15, 2017: ARCA Biopharma Announces First Quarter 2017 Financial Results 33
May 15, 2017: ARCA Biopharma Q1 net loss increases 34
Mar 21, 2017: ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update 35
Corporate Communications 37
Feb 21, 2017: Anders Hove, MD Joins ARCA biopharma Board of Directors 37
Product News 38
03/06/2017: ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 38
01/18/2017: ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 39
Clinical Trials 40
Feb 26, 2018: ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial 40
Jan 08, 2018: ARCA biopharma Announces Completion of GENETIC-AF Phase IIB Clinical Trial 42
Aug 16, 2017: ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial 43
Aug 09, 2017: ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis 44
Jun 20, 2017: ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017 45
May 15, 2017: ARCA Biopharma Provides Update on Gencaro 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ARCA biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12
ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13
Arca Biopharma Raises USD37 Million in Private Placement of Units 14
ARCA biopharma Files Registration Statement For Public Offering Of Securities For US$75 Million 16
Arca Biopharma Completes Public Offering Of Shares For US$8.7 Million 17
Arca Biopharma Completes Public Offering Of Preferred Shares For US$20 Million 18
Arca Biopharma Completes Private Placement Of Securities For US$1.25 Million 19
ARCA biopharma Completes Public Offering Of Shares For US$0.7 Million 20
Arca Biopharma Completes Private Placement Of Units For US$0.25 Million 21
ARCA biopharma Completes Private Placement Of Units For US$0.325 Million 22
ARCA biopharma Completes Public Offering Of Units For US$1 Million 23
ARCA biopharma Inc, Key Competitors 25
ARCA biopharma Inc, Key Employees 26

List of Figures
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ARCA biopharma Inc (ABIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fortum Corporation:企業の戦略・SWOT・財務情報
    Fortum Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Micropole SA (MUN):企業の財務・戦略的SWOT分析
    Micropole SA (MUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Elavon, Inc.:企業の戦略・SWOT・財務情報
    Elavon, Inc. - Strategy, SWOT and Corporate Finance Report Summary Elavon, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Rhino Resource Partners LP:企業の戦略・SWOT・財務情報
    Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report Summary Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Alliance Data Systems Corp (ADS):企業の財務・戦略的SWOT分析
    Alliance Data Systems Corp (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Evraz Plc:企業の戦略・SWOT・財務情報
    Evraz Plc - Strategy, SWOT and Corporate Finance Report Summary Evraz Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Bangladesh Power Development Board-エネルギー分野:企業M&A・提携分析
    Summary Bangladesh Power Development Board (BPDB) is an integrated energy statutory board. It generates electricity through owned power plants and procures electricity from public and private generation companies. The board utilizes gas, coal, hydro, furnace oil, and diesel as fuel source for electr …
  • Lyft Inc (LYFT)
    Lyft Inc (LYFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • IDBI Bank Ltd:企業の戦略・SWOT・財務情報
    IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Holding Slovenske elektrarne d.o.o.:企業の戦略的SWOT分析
    Holding Slovenske elektrarne d.o.o. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Xencor Inc (XNCR):企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • Oversea-Chinese Banking Corp Ltd:企業の戦略・SWOT・財務情報
    Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Creightons plc:企業の戦略・SWOT・財務情報
    Creightons plc - Strategy, SWOT and Corporate Finance Report Summary Creightons plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cintas Corp (CTAS):企業の財務・戦略的SWOT分析
    Cintas Corp (CTAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Dev Information Technology Ltd (DEVIT):企業の財務・戦略的SWOT分析
    Dev Information Technology Ltd (DEVIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • The Ensign Group Inc (ENSG):企業の財務・戦略的SWOT分析
    The Ensign Group Inc (ENSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Alfred E. Tiefenbacher (GmbH & Co KG)-製薬・医療分野:企業M&A・提携分析
    Summary Alfred E. Tiefenbacher (GmbH & Co KG) (AET) is a healthcare products provider that develops active pharmaceuticals ingredients. The company’s products comprise cytotoxic drugs, hormones, OTC drugs, controlled drugs, herbal drugs, high potent drugs, new combination products, inhaler technolog …
  • Main Street America Group Inc:企業の戦略的SWOT分析
    Main Street America Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Al Jaber Group:企業の戦略・SWOT・財務分析
    Al Jaber Group - Strategy, SWOT and Corporate Finance Report Summary Al Jaber Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆